Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Preliminary evaluation of prostate cancer metastatic risk biomarkers.

Paris PL, Weinberg V, Simko J, Andaya A, Albo G, Rubin MA, Carroll PR, Collins C.

Int J Biol Markers. 2005 Jul-Sep;20(3):141-5.

PMID:
16247872
2.

Evaluating a marker's contribution to a nomogram: the GEMCaP example.

Kattan MW.

Clin Cancer Res. 2010 Jan 1;16(1):1-3. doi: 10.1158/1078-0432.CCR-09-2946.

3.

Cost effectiveness of risk-prediction tools in selecting patients for immediate post-prostatectomy treatment.

Zubek VB, Konski A.

Mol Diagn Ther. 2009;13(1):31-47. doi: 10.2165/01250444-200913010-00006.

PMID:
19351214
4.

External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy.

Shariat SF, Walz J, Roehrborn CG, Zlotta AR, Perrotte P, Suardi N, Saad F, Karakiewicz PI.

J Clin Oncol. 2008 Mar 20;26(9):1526-31. doi: 10.1200/JCO.2007.12.4669.

PMID:
18349404
5.

High-resolution array comparative genomic hybridization of chromosome arm 8q: evaluation of genetic progression markers for prostate cancer.

van Duin M, van Marion R, Vissers K, Watson JE, van Weerden WM, Schröder FH, Hop WC, van der Kwast TH, Collins C, van Dekken H.

Genes Chromosomes Cancer. 2005 Dec;44(4):438-49.

PMID:
16130124
6.

Cross-cultural validation of a prognostic tool: example of the Kattan preoperative nomogram as a predictor of prostate cancer recurrence after radical prostatectomy.

Rouprêt M, Hupertan V, Comperat E, Drouin SJ, Phé V, Xylinas E, Demanse D, Sibony M, Richard F, Cussenot O.

BJU Int. 2009 Sep;104(6):813-7; discussion 817-8. doi: 10.1111/j.1464-410X.2009.08473.x.

7.

A group of genome-based biomarkers that add to a Kattan nomogram for predicting progression in men with high-risk prostate cancer.

Paris PL, Weinberg V, Albo G, Roy R, Burke C, Simko J, Carroll P, Collins C.

Clin Cancer Res. 2010 Jan 1;16(1):195-202. doi: 10.1158/1078-0432.CCR-09-0948.

8.

Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors.

Paris PL, Andaya A, Fridlyand J, Jain AN, Weinberg V, Kowbel D, Brebner JH, Simko J, Watson JE, Volik S, Albertson DG, Pinkel D, Alers JC, van der Kwast TH, Vissers KJ, Schroder FH, Wildhagen MF, Febbo PG, Chinnaiyan AM, Pienta KJ, Carroll PR, Rubin MA, Collins C, van Dekken H.

Hum Mol Genet. 2004 Jul 1;13(13):1303-13.

9.

Performance of the Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP) tumor biomarker for identifying recurrent disease in African American patients.

Levin AM, Lindquist KJ, Avila A, Witte JS, Paris PL, Rybicki BA.

Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1677-82. doi: 10.1158/1055-9965.EPI-13-1124.

10.

Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy.

Henshall SM, Horvath LG, Quinn DI, Eggleton SA, Grygiel JJ, Stricker PD, Biankin AV, Kench JG, Sutherland RL.

J Natl Cancer Inst. 2006 Oct 4;98(19):1420-4.

11.

Local and systemic therapy for patients with metastatic prostate cancer: should the primary tumor be treated?

Canby-Hagino ED, Swanson GP, Crawford ED, Basler JW, Hernandez J, Thompson IM.

Curr Urol Rep. 2005 May;6(3):183-9. Review.

PMID:
15869722
12.

Genomic signatures associated with the development, progression, and outcome of prostate cancer.

Mendiratta P, Febbo PG.

Mol Diagn Ther. 2007;11(6):345-54. Review.

PMID:
18078352
13.

External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score.

Zhao KH, Hernandez DJ, Han M, Humphreys EB, Mangold LA, Partin AW.

Urology. 2008 Aug;72(2):396-400. doi: 10.1016/j.urology.2007.11.165.

PMID:
18372031
14.

Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.

Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL.

Ann Intern Med. 2008 Mar 18;148(6):435-48. Review. Erratum in: Ann Intern Med. 2008 Jun 3;148(11):888.

PMID:
18252677
15.

Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy.

Simmons MN, Stephenson AJ, Klein EA.

Eur Urol. 2007 May;51(5):1175-84. Review.

PMID:
17240528
16.

Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.

May M, Knoll N, Siegsmund M, Fahlenkamp D, Vogler H, Hoschke B, Gralla O.

J Urol. 2007 Nov;178(5):1957-62; discussion 1962.

PMID:
17868719
17.

Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.

Rosenbaum E, Hoque MO, Cohen Y, Zahurak M, Eisenberger MA, Epstein JI, Partin AW, Sidransky D.

Clin Cancer Res. 2005 Dec 1;11(23):8321-5.

18.

Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.

Cheng L, Jones TD, Lin H, Eble JN, Zeng G, Carr MD, Koch MO.

J Urol. 2005 Dec;174(6):2181-5.

PMID:
16280760
19.

Prostatic fatty acids and cancer recurrence after radical prostatectomy for early-stage prostate cancer.

Freeman VL, Flanigan RC, Meydani M.

Cancer Causes Control. 2007 Mar;18(2):211-8.

PMID:
17216324
20.

Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.

Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Bergstralh EJ, Karnes RJ, Frank I, Blute ML.

J Urol. 2007 Sep;178(3 Pt 1):864-70; discussion 870-1.

PMID:
17631342
Items per page

Supplemental Content

Support Center